Comparative anti-gonococcal activity of S-565, a new rifamycin

International Journal of Antimicrobial Agents

Volumn 7, Issue 4, 1996, Pages 247-250

  Hamilton Miller, J M T ^a   Bruzzese, T ^b   Nonis, A ^b   Shah, S ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b Società Prodotti Antibiotici   (Italy)

Author keywords

Neisseria gonorrhoeae; rifampicin; S 565

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; CIPROFLOXACIN; RIFAMPICIN; RIFAMYCIN DERIVATIVE; S 565; SPECTINOMYCIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; CONTROLLED STUDY; CROSS RESISTANCE; DRUG HALF LIFE; DRUG RESISTANCE; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030267102     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(96)00331-7     Document Type: Article

References (7)

1. [1] Arioli V, Berti M, Carniti G, Randisi E, Rossi E, Scotti R. Antibacterial activity of DL 473, a new semisynthetic rifamycin derivative. J Antibiot, 1981;34:1026-1032.
2. [2] Della Bruna C, Ungheri D, Sebben G, Sanfilippo A. Laboratory evaluation of a new long-acting 3-azinomethylrifamycin, FCE 22250. J Antibiot. 1985;38:779-786.
3. [3] Strippoli V, Bruzzese T, Galli R, Simonetti N. The antibacterial activity of a new 3-azinomethylrifamycin. Il Farmaco, Ed Sci, 1988;43:619-625.
4. [4] Zanetti S, Usai D, Nonis A, Fadda G. In-vitro activity of 3-azinomethyl-rifamycin (SPA-S-565) against Chlamydia trachomatis. J Antimicrob Chemother, 1996;37:357-359.
5. [5] Hafiz S, McEntergart MG. Prolonged survival of Neisseria gonorrhoeae in a new liquid medium. Br J Vener Dis, 1976;52:381-383.
6. [6] Hamilton-Miller JMT. Calculating MIC50. J Antimicrob Chemother, 1991;27:863-864.
7. [7] Szybalski W, Bryson V. Genetic studies on microbial cross-resistance to toxic agents. I. Cross-resistance of Escherichia coli to fifteen antibiotics. J Bacteriol, 1952;64:489-499.